As a result, clinical trials in EGFR-amplified patients of anti-EGFR therapies have been performed (INTELLANCE1—NCT02573324, INTELLANCE2—NCT02343406) but have not yet shown sustained clinical benefit in primary glioblastoma [5]. Here, EGFR is linked to glioblastoma.